Humoral and cellular immune abnormalities in adult hemophiliacs followed over a 2-year period.
Immune function was assessed in 93 adult hemophiliacs in the 2 years prior to HTLV-III antibody testing of blood donors and routine heat treatment of coagulation factor concentrates. Parameters of humoral and cellular immunity studied included serum complements, immunoglobulins, immune complexes, blood cell counts, lymphocyte subsets, lymphocyte transformation, 2-5A synthetase, serology for HTLV-III and hepatitis B, skin tests, and clinical status. HTLV-III seropositivity was significantly more prevalent in patients treated with factor VIII concentrate; seropositive patients had a higher proportion of abnormal test results and were more symptomatic. Although many subjects had abnormal test results, specific test results generally did not correlate with type of blood component received or time of preceding treatment. The proportion of tests abnormal in individual patients was correlated with the intensity of factor replacement therapy when the time interval from the last treatment was a covariate. While T8+ lymphocytes were increased and T4/T8 ratios were decreased in many patients, significantly reduced T4+ lymphocytes were seen only in seropositive patients and in those treated with factor VIII concentrate. Neither seropositivity nor presence of symptoms correlated with abnormal lymphocyte mitogenic response or 2-5A synthetase levels, but synthetase levels were increased in 65% of patients tested. Over the 2-year study period, no significant deterioration of clinical or laboratory variables was observed in the patients. Abnormalities of immune function were found to be common in hemophiliacs regardless of type of treatment or of evidence of HTLV-III infection.
D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D000936:Antigen-Antibody Complex / Q000032:analysis; D001772:Blood Cell Count; D003165:Complement System Proteins / Q000032:analysis; D005500:Follow-Up Studies; D015483:HIV Antibodies; D006467:Hemophilia A / Q000276:immunology* / Q000628:therapy; D006801:Humans; D007111:Immunity, Cellular; D007136:Immunoglobulins / Q000032:analysis; D007372:Interferons / Q000494:pharmacology; D008214:Lymphocytes / Q000145:classification / Q000276:immunology; D013997:Time Factors
D000914:Antibodies, Viral; D000936:Antigen-Antibody Complex; D015483:HIV Antibodies; D007136:Immunoglobulins; D003165:Complement System Proteins; D007372:Interferons